Bio SB performs R&D, production, distribution and marketing of unique products for Immunohistochemistry (IHC), Immunocytochemistry (ICC), Fluorescent in situ hybridization (FISH), Chromogenic in situ hybridization (CISH), Liquid-Based Cytology (LBC) and Polymerase Chain Reaction (PCR) technologies that meet the highest international standards for applications in Molecular Pathology, Cancer Research, Microbiology, Immunology and Genetics. BIO SB manufactures and develops products in accordance with FDA QSR 21 CFR Part 820 cGMP.
This antibody has been used for evaluating the primary site of a metastatic carcinoma of unknown origin and distinguishing between benign and malignant lesions. It is believed that CA15-3 reacts primarily with the DF3-antigen, a 300 kDa mucin-like glycoprotein present on the apical border of secretory mammary epithelial cells. CA15-3 has been detected with immunohistochemistry in a wide spectrum of carcinomas, including Breast Carcinomas (ductal and lobular), Sarcomas (Synovial Sarcoma and Malignant Fibrous Histiocytomas), and Lung Carcinomas. CA15-3 can be used as a supplementary marker for epithelial differentiation. CA15-3 does not stain Melanomas or Ewing’s Sarcomas. Approximately 30% of Hepatocellular Carcinomas are positive for CA15-3.
Breast, Pancreas, Salivary Gland
CA15-3 is a mouse monoclonal antibody derived from cell culture supernatant that is concentrated, dialyzed, filter sterilized and diluted in buffer pH 7.5, containing BSA and sodium azide as a preservative.
Note: For concentrated antibodies, please centrifuge prior to use to ensure recovery of all product.